Taysha Gene Therapies, Inc. $TSHA Shares Bought by Granahan Investment Management LLC

Granahan Investment Management LLC increased its position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 25.5% in the 1st quarter, HoldingsChannel.com reports. The firm owned 883,241 shares of the company’s stock after acquiring an additional 179,270 shares during the period. Granahan Investment Management LLC’s holdings in Taysha Gene Therapies were worth $3,948,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Vestal Point Capital LP increased its position in shares of Taysha Gene Therapies by 150.0% in the fourth quarter. Vestal Point Capital LP now owns 13,750,000 shares of the company’s stock valued at $75,625,000 after buying an additional 8,250,000 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth about $11,178,000. Barclays PLC boosted its position in shares of Taysha Gene Therapies by 1,042.8% in the 3rd quarter. Barclays PLC now owns 5,148,112 shares of the company’s stock worth $16,834,000 after buying an additional 4,697,611 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new stake in Taysha Gene Therapies in the 4th quarter valued at about $20,471,000. Finally, State Street Corp grew its stake in Taysha Gene Therapies by 49.1% in the 4th quarter. State Street Corp now owns 10,790,084 shares of the company’s stock valued at $59,345,000 after acquiring an additional 3,553,619 shares during the last quarter. 77.70% of the stock is currently owned by hedge funds and other institutional investors.

Taysha Gene Therapies Trading Down 5.3%

Taysha Gene Therapies stock opened at $5.52 on Friday. The stock has a 50-day moving average price of $5.97 and a 200 day moving average price of $5.36. Taysha Gene Therapies, Inc. has a 52 week low of $2.53 and a 52 week high of $7.30. The stock has a market cap of $1.59 billion, a PE ratio of -14.53 and a beta of 1.17. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last released its earnings results on Wednesday, May 6th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). Equities research analysts predict that Taysha Gene Therapies, Inc. will post -0.49 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Needham & Company LLC restated a “buy” rating and set a $12.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, June 30th. Robert W. Baird increased their price target on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Canaccord Genuity Group increased their price target on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, April 6th. Citigroup reissued an “outperform” rating on shares of Taysha Gene Therapies in a research note on Tuesday, June 23rd. Finally, Citizens Jmp reaffirmed a “market outperform” rating and issued a $11.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, July 2nd. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Taysha Gene Therapies currently has an average rating of “Buy” and an average price target of $12.77.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The shares were sold at an average price of $6.24, for a total value of $1,248,000.00. Following the completion of the transaction, the insider owned 936,410 shares of the company’s stock, valued at $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.48% of the stock is currently owned by corporate insiders.

Taysha Gene Therapies Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.